Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 8/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.49 |
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857264 | 0.97 | USP30 (0.47) | HCRTR2HCRTR1SCDUSP30GPR119 | |
| SCHEMBL17063834 | 0.90 | HCRTR1 (0.57) | HCRTR2HCRTR1SCDUSP30MAPT | |
| SCHEMBL17063835 | 0.90 | HCRTR1 (0.57) | HCRTR2HCRTR1SCDUSP30MAPT | |
| SCHEMBL21065089 | 0.84 | HCRTR1 (0.57) | HCRTR2HCRTR1USP30MAPTNPSR1 | |
| SCHEMBL21065088 | 0.84 | HCRTR1 (0.57) | HCRTR2HCRTR1USP30MAPTNPSR1 | |
| SCHEMBL4596239 | 0.83 | HCRTR1 (0.45) | HCRTR2HCRTR1USP30GPR119UCHL1 | |
| SCHEMBL4594977 | 0.83 | HCRTR1 (0.45) | HCRTR2HCRTR1USP30GPR119UCHL1 | |
| SCHEMBL3859454 | 0.83 | SCD5 (0.48) | HCRTR2HCRTR1USP30GPR119MAPT | |
| SCHEMBL3852498 | 0.83 | SCD5 (0.48) | HCRTR2HCRTR1USP30GPR119MAPT | |
| SCHEMBL3916610 | 0.82 | HCRTR1 (0.53) | HCRTR2HCRTR1USP30UCHL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579349-B2 | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| EP-1678169-B1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | IGF1R, IGFBP1, GPR119 | HCRTR2 3725/4885HCRTR1 3664/4885SCD 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.